Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 261

1.

Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases.

Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M.

Clin Breast Cancer. 2012 Aug;12(4):247-58. doi: 10.1016/j.clbc.2012.04.001. Epub 2012 Jun 12.

PMID:
22694824
2.

Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.

Xie J, Namjoshi M, Wu EQ, Parikh K, Diener M, Yu AP, Guo A, Culver KW.

J Manag Care Pharm. 2011 Oct;17(8):621-43.

3.

Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.

Stopeck A, Rader M, Henry D, Danese M, Halperin M, Cong Z, Qian Y, Dansey R, Chung K.

J Med Econ. 2012;15(4):712-23. doi: 10.3111/13696998.2012.675380. Epub 2012 Mar 27.

PMID:
22409231
4.

Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer.

Snedecor SJ, Carter JA, Kaura S, Botteman MF.

Clin Ther. 2012 Jun;34(6):1334-49. doi: 10.1016/j.clinthera.2012.04.008. Epub 2012 May 11.

PMID:
22578308
5.

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis.

Snedecor SJ, Carter JA, Kaura S, Botteman MF.

J Med Econ. 2013;16(1):19-29. doi: 10.3111/13696998.2012.719054. Epub 2012 Sep 5.

PMID:
22870908
6.

Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours.

Carter JA, Joshi AD, Kaura S, Botteman MF.

Pharmacoeconomics. 2012 May;30(5):373-86. doi: 10.2165/11631390-000000000-00000. Review.

PMID:
22500986
7.

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A.

J Clin Oncol. 2010 Dec 10;28(35):5132-9. doi: 10.1200/JCO.2010.29.7101. Epub 2010 Nov 8.

PMID:
21060033
8.

Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid.

Martin M, Bell R, Bourgeois H, Brufsky A, Diel I, Eniu A, Fallowfield L, Fujiwara Y, Jassem J, Paterson AH, Ritchie D, Steger GG, Stopeck A, Vogel C, Fan M, Jiang Q, Chung K, Dansey R, Braun A.

Clin Cancer Res. 2012 Sep 1;18(17):4841-9. Epub 2012 Aug 14.

9.

Comparing cost-effectiveness analyses of denosumab versus zoledronic acid for the treatment of bone metastases.

Koo K, Lam K, Mittmann N, Konski A, Dennis K, Zeng L, Lam H, Chow E.

Support Care Cancer. 2013 Jun;21(6):1785-91. doi: 10.1007/s00520-013-1790-y. Epub 2013 Mar 22. Review.

PMID:
23519570
10.

Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.

Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S.

J Clin Oncol. 2005 May 20;23(15):3314-21. Epub 2005 Feb 28.

PMID:
15738536
11.

Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications.

Hirsh V, Tchekmedyian NS, Rosen LS, Zheng M, Hei YJ.

Clin Lung Cancer. 2004 Nov;6(3):170-4.

PMID:
15555218
12.

Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.

McKeage K, Plosker GL.

Pharmacoeconomics. 2008;26(3):251-68. Review.

PMID:
18282018
13.

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H.

J Clin Oncol. 2011 Mar 20;29(9):1125-32. doi: 10.1200/JCO.2010.31.3304. Epub 2011 Feb 22.

PMID:
21343556
14.

Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer.

Carter JA, Botteman MF.

Expert Rev Pharmacoecon Outcomes Res. 2012 Aug;12(4):425-37. doi: 10.1586/erp.12.31. Epub 2012 Apr 27. Review.

PMID:
22540167
15.

Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours.

Ford J, Cummins E, Sharma P, Elders A, Stewart F, Johnston R, Royle P, Jones R, Mulatero C, Todd R, Mowatt G.

Health Technol Assess. 2013 Jul;17(29):1-386. doi: 10.3310/hta17290. Review.

16.
17.

Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.

Cartenì G, Bordonaro R, Giotta F, Lorusso V, Scalone S, Vinaccia V, Rondena R, Amadori D.

Oncologist. 2006 Jul-Aug;11(7):841-8.

18.

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.

Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J.

Cancer. 2004 Jun 15;100(12):2613-21.

19.

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.

Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S.

Eur J Cancer. 2012 Nov;48(16):3082-92. doi: 10.1016/j.ejca.2012.08.002. Epub 2012 Sep 10.

PMID:
22975218
20.

Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice.

Delea T, McKiernan J, Brandman J, Edelsberg J, Sung J, Raut M, Oster G.

J Support Oncol. 2006 Jul-Aug;4(7):341-7.

PMID:
16892696

Supplemental Content

Support Center